OncoSignal
Live from Open Targets Platform, fetched 2026-11-12 00:34 UTC. Every row links to its source record.

DDX41 DEAD-box helicase 41

ENSG00000183258 · protein coding · Open Targets profile

Multifunctional protein that participates in many aspects of cellular RNA metabolism. Plays pivotal roles in innate immune sensing and hematopoietic homeostasis (PubMed:34473945). Recognizes foreign or self-nucleic acids generated during microbial infection, thereby initiating anti-pathogen responses (PubMed:23222971). Mechanistically, phosphorylation by BTK allows binding to dsDNA leading to interaction with STING1 (PubMed:25704810). Modulates the homeostasis of dsDNA through its ATP-dependent DNA-unwinding activity and ATP-independent strand-annealing activity (PubMed:35613581). In turn, induces STING1- mediated type I interferon and cytokine responses to DNA and DNA viruses (PubMed:35613581). Selectively modulates the transcription of certain immunity-associated genes by regulating their alternative splicing (PubMed:33650667). Binds to RNA (R)-loops, structures consisting of DNA/RNA hybrids and a displaced strand of DNA that occur during transcription, and prevents their accumulation, thereby maintaining genome stability (PubMed:36229594). Also participates in pre-mRNA splicing, translational regulation and snoRNA processing, which is essential for ribosome biogenesis (PubMed:36229594, PubMed:36780110). {ECO:0000250|UniProtKB:Q91VN6, ECO:0000269|PubMed:23222971, ECO:0000269|PubMed:25704810, ECO:0000269|PubMed:25920683, ECO:0000269|PubMed:33650667, ECO:0000269|PubMed:34473945, ECO:0000269|PubMed:35613581, ECO:0000269|PubMed:36229594, ECO:0000269|PubMed:36780110}.

In 11 of 15 cancers, the evidence for DDX41 comes mainly from inherited variants

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751DDX41-related hematologic malignancy pr…DDX41-related hematologic malignancy predisposition syndromeDDX41-related hematologic malignancy predisposition syndrome: germline 0.92myelodysplastic syndromemyelodysplastic syndromemyelodysplastic syndrome: germline 0.93acute myeloid leukemiaacute myeloid leukemiaacute myeloid leukemia: germline 0.91myelodysplastic syndrome with excess bl…myelodysplastic syndrome with excess blastsmyelodysplastic syndrome with excess blasts: germline 0.96myeloid leukemiamyeloid leukemiamyeloid leukemia: germline 0.91adult acute myeloid leukemiaadult acute myeloid leukemiaadult acute myeloid leukemia: germline 0.81chronic myeloid leukemiachronic myeloid leukemiaKostmann syndromeKostmann syndromeinherited acute myeloid leukemiainherited acute myeloid leukemiainherited acute myeloid leukemia: germline 0.56hematopoietic and lymphoid cell neoplasmhematopoietic and lymphoid cell neoplasmhematopoietic and lymphoid cell neoplasm: germline 0.33hematopoietic and lymphoid system neopl…hematopoietic and lymphoid system neoplasmhematopoietic and lymphoid system neoplasm: germline 0.29leukemialeukemialeukemia: germline 0.24hereditary cancerhereditary cancerhereditary cancer: germline 0.19melanomamelanomaliver cancerliver cancer

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Small molecule
Structure with Ligand
PROTAC
UniProt Ubiquitination, Database Ubiquitination, Half-life Data

gnomAD loss of function constraint: o/e 0.634190022945404 (upper bound 0.8027300238609314). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of DDX41's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of DDX41's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.